Adepitan A Owosho1, Adeola M Ladeji2, Kehinde E Adebiyi2, Mofoluwaso A Olajide2, Ikechukwu S I Okoye2, Temitope Kehinde3, Ngozi N Nwizu4, Kurt F Summersgill5. 1. Missouri School of Dentistry and Oral Health, A.T. Still University, 800 W Jefferson Street, Kirksville, MO, USA. adepitanowosho@atsu.edu. 2. Department of Oral Pathology and Oral Medicine, Faculty of Dentistry, Lagos State University College of Medicine, Lagos, Nigeria. 3. Department of Pathology, Anatomy and Laboratory Medicine, West Virginia University, Morgantown, WV, USA. 4. Department of Diagnostic and Biomedical Science, School of Dentistry, The University of Texas, Health Science Center at Houston, Houston, TX, USA. 5. Department of Diagnostic Sciences, School of Dental Medicine, University of Pittsburgh, Pittsburgh, PA, USA.
Abstract
PURPOSE: The aim of this study is to investigate the presence and prevalence of BRAF V600E mutation in ameloblastomas using anti-BRAF V600E monoclonal antibody (VE1 clone) and to identify any clinicopathologic correlation with BRAF V600E mutation in ameloblastoma. MATERIALS AND METHODS: The pathology files of the Department of Oral Pathology and Oral Medicine, Faculty of Dentistry, Lagos State University College of Medicine, Lagos, Nigeria, were searched for the diagnosis of ameloblastoma from 2016 to 2020. Archived non-decalcified formalin-fixed paraffin-embedded tissue underwent immunohistochemistry using anti-BRAF V600E antibody at the University of Pittsburgh, Pennsylvania. Clinicopathologic data such as age at diagnosis, gender, jaw bone involved (mandible or maxilla), tumor location (anterior or posterior) and histologic subtype were collected. The clinicopathologic parameters were analyzed using Chi-square test and Fisher's exact test according to the BRAF status. RESULTS: Forty-four cases of ameloblastoma were retrieved. The male to female ratio was 1.32:1. The average age of patients at diagnosis was 33.3 years. Thirty-nine cases were located in the mandible and 5 cases in the maxilla. Only cases in the mandible were positive for anti-BRAF V600E antibody (n = 15/39; 38.5%). There was a significant correlation between BRAF V600E expression in mandibular tumors and histologic subtype (p = 0.02); however, no significance was observed for gender, age and tumor location. CONCLUSION: BRAF V600E mutation preferentially occurs in mandibular ameloblastomas, especially in non-plexiform ameloblastomas. These patients may benefit therapeutically from the use of BRAF inhibitors.
PURPOSE: The aim of this study is to investigate the presence and prevalence of BRAFV600E mutation in ameloblastomas using anti-BRAFV600E monoclonal antibody (VE1 clone) and to identify any clinicopathologic correlation with BRAFV600E mutation in ameloblastoma. MATERIALS AND METHODS: The pathology files of the Department of Oral Pathology and Oral Medicine, Faculty of Dentistry, Lagos State University College of Medicine, Lagos, Nigeria, were searched for the diagnosis of ameloblastoma from 2016 to 2020. Archived non-decalcified formalin-fixed paraffin-embedded tissue underwent immunohistochemistry using anti-BRAFV600E antibody at the University of Pittsburgh, Pennsylvania. Clinicopathologic data such as age at diagnosis, gender, jaw bone involved (mandible or maxilla), tumor location (anterior or posterior) and histologic subtype were collected. The clinicopathologic parameters were analyzed using Chi-square test and Fisher's exact test according to the BRAF status. RESULTS: Forty-four cases of ameloblastoma were retrieved. The male to female ratio was 1.32:1. The average age of patients at diagnosis was 33.3 years. Thirty-nine cases were located in the mandible and 5 cases in the maxilla. Only cases in the mandible were positive for anti-BRAFV600E antibody (n = 15/39; 38.5%). There was a significant correlation between BRAFV600E expression in mandibular tumors and histologic subtype (p = 0.02); however, no significance was observed for gender, age and tumor location. CONCLUSION:BRAFV600E mutation preferentially occurs in mandibular ameloblastomas, especially in non-plexiform ameloblastomas. These patients may benefit therapeutically from the use of BRAF inhibitors.
Authors: Robert T Sweeney; Andrew C McClary; Benjamin R Myers; Jewison Biscocho; Lila Neahring; Kevin A Kwei; Kunbin Qu; Xue Gong; Tony Ng; Carol D Jones; Sushama Varma; Justin I Odegaard; Toshihiro Sugiyama; Souichi Koyota; Brian P Rubin; Megan L Troxell; Robert J Pelham; James L Zehnder; Philip A Beachy; Jonathan R Pollack; Robert B West Journal: Nat Genet Date: 2014-05-25 Impact factor: 38.330
Authors: Andrew C McClary; Robert B West; Ashley C McClary; Jonathan R Pollack; Nancy J Fischbein; Christopher F Holsinger; John Sunwoo; A Dimitrios Colevas; Davud Sirjani Journal: Eur Arch Otorhinolaryngol Date: 2015-04-30 Impact factor: 2.503
Authors: Dinaz Ghandhi; Ashraf F Ayoub; M Anthony Pogrel; Gordon MacDonald; Laetitia M Brocklebank; Khursheed F Moos Journal: J Oral Maxillofac Surg Date: 2006-07 Impact factor: 1.895
Authors: Kari J Kurppa; Javier Catón; Peter R Morgan; Ari Ristimäki; Blandine Ruhin; Jari Kellokoski; Klaus Elenius; Kristiina Heikinheimo Journal: J Pathol Date: 2014-01-31 Impact factor: 7.996